Our top pick for
Building a portfolio
Natus Medical Incorporated is a medical devices business based in the US. Natus Medical Incorporated shares (NTUS) are listed on the NASDAQ and all prices are listed in US Dollars. Natus Medical Incorporated employs 1,420 staff and has a trailing 12-month revenue of around USD0.00.
|52-week range||USD$16.38 - USD$28.83|
|50-day moving average||USD$25.89|
|200-day moving average||USD$22.66|
|Wall St. target price||USD$36.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-1.29|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Natus Medical Incorporated stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Natus Medical Incorporated's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Natus Medical Incorporated's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 65x. In other words, Natus Medical Incorporated shares trade at around 65x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Natus Medical Incorporated's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$18.2 million.
The EBITDA is a measure of a Natus Medical Incorporated's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$415.7 million|
|Gross profit TTM||USD$236.2 million|
|Return on assets TTM||-0.99%|
|Return on equity TTM||-4.02%|
|Market capitalisation||USD$947.1 million|
TTM: trailing 12 months
There are currently 867,081 Natus Medical Incorporated shares held short by investors – that's known as Natus Medical Incorporated's "short interest". This figure is 6.2% up from 816,298 last month.
There are a few different ways that this level of interest in shorting Natus Medical Incorporated shares can be evaluated.
Natus Medical Incorporated's "short interest ratio" (SIR) is the quantity of Natus Medical Incorporated shares currently shorted divided by the average quantity of Natus Medical Incorporated shares traded daily (recently around 166746.34615385). Natus Medical Incorporated's SIR currently stands at 5.2. In other words for every 100,000 Natus Medical Incorporated shares traded daily on the market, roughly 5200 shares are currently held short.
However Natus Medical Incorporated's short interest can also be evaluated against the total number of Natus Medical Incorporated shares, or, against the total number of tradable Natus Medical Incorporated shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Natus Medical Incorporated's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Natus Medical Incorporated shares in existence, roughly 30 shares are currently held short) or 0.0307% of the tradable shares (for every 100,000 tradable Natus Medical Incorporated shares, roughly 31 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Natus Medical Incorporated.
Find out more about how you can short Natus Medical Incorporated stock.
We're not expecting Natus Medical Incorporated to pay a dividend over the next 12 months.
Over the last 12 months, Natus Medical Incorporated's shares have ranged in value from as little as $16.38 up to $28.83. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Natus Medical Incorporated's is 0.5372. This would suggest that Natus Medical Incorporated's shares are less volatile than average (for this exchange).
Natus Medical Incorporated provides medical device solutions focusing on the diagnosis and treatment of patients with central nervous and sensory system disorders worldwide. It offers products and services used for the screening, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological and neurosurgical treatments, epilepsy, sleep disorders, and neuromuscular diseases. The company also provides computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology; and software systems for managing and tracking disorders and diseases for public health laboratories. In addition, it offers electroencephalography, long term monitoring, intensive care unit monitoring, electromyography, sleep analysis or polysomnography, and intra-operative monitoring solutions. Further, the company provides hearing assessment, screening, and instrument fitting solutions; jaundice management products; brain injury products; and eye imaging systems and products used in the advanced science and practice of neonatal and pediatric retinal imaging. Additionally, it offers NICVIEW, a live streaming video for families with babies in the neonatal intensive care unit (NICU); essential products used in the everyday operation of NICU; balance assessment systems to evaluate patients with balance disorders. The company also provides computer-based audiological, otoneurologic, and vestibular instrumentation for hearing and balance care professionals.
Steps to owning and managing ZTO, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZOM, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZI, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZKIN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZION, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZIONL, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZNTL, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZGYH, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZEAL, with 24-hour and historical pricing before you buy.
Steps to owning and managing CTIB, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.